N
KYMR icon

Natixis’s Kymera Therapeutics KYMR Stock Holding History

Natixis’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,595
Closed -$113K – 1152
2025
Q2 		$113K Sell
2,595
-10,079
-80% -$347K ﹤0.01% 826
2025
Q1 		$356K Buy
+12,674
New +$462K ﹤0.01% 696
2024
Q2 		– Sell
-1,979
Closed -$79.6K – 1079
2024
Q1 		$79.6K Sell
1,979
-1,992
-50% -$71.3K ﹤0.01% 793
2023
Q4 		$101K Sell
3,971
-209
-5% -$3.74K ﹤0.01% 773
2023
Q3 		$58.1K Buy
+4,180
New +$84K ﹤0.01% 814
2022
Q2 		– Sell
-8,803
Closed -$373K – 1268
2022
Q1 		$373K Sell
8,803
-8,345
-49% -$352K ﹤0.01% 1028
2021
Q4 		$1.09M Sell
17,148
-38,991
-69% -$2.27M ﹤0.01% 907
2021
Q3 		$3.3M Buy
56,139
+49,575
+755% +$2.87M 0.01% 634
2021
Q2 		$318K Buy
+6,564
New +$285K ﹤0.01% 779

Other funds holding KYMR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return